Europe
Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, today announced the final close of its fifth-generation fund Wellington Partners Life Science Fund V (WPLS-V).
The product was originally licensed in a partnership deal in 2015, which has now been terminated in what is being called a strategic portfolio decision by Janssen.
The U.S. Food and Drug Administration approved Bayer’s Nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer.
The fund plans to build a portfolio of about 15 to 20 companies, with a focus on novel biotechnology platforms, new therapeutics and medical devices, as well as diagnostics and digital medicine.
Fluidity One-W wins SLAS new product award for enabling in-solution interaction analysis of challenging proteins
Hutchison China MediTech Limited announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.
Medigene AG announced its participation at the following upcoming investor conferences:
Biogen and Alkermes announced positive topline data from EVOLVE-MS-2, a Phase III trial of diroximel fumarate for relapsing-remitting multiple sclerosis compared to Tecfidera.
Teva Pharmaceuticals, Endo Pharmaceuticals and Taikoku Pharma entered into settlement agreements with the State of California for a total of almost $70 million. The settlements were over non-competitive, inter-company deals that prevented cheaper drugs from entering the market.
Silence Therapeutics, PLC is pleased to announce that further to the announcements on 18 July 2019 detailing the Company’s collaboration with and equity investment by Mallinckrodt plc, Steven Romano, MD, has joined the Board of Silence as a Non-Executive Director.
PRESS RELEASES